Treatment of patients with acute and subacute dorsalgia

Objective: to investigate the efficiency of treatment for acute and subacute dorsalgia, by providing information to patients and by using nonsteroidal anti-inflammatory drugs (NSAIDs) without conducting physical therapy, reflexotherapy, and manual therapy. Patients and methods. A total of 140 patients (87 women and 53 men; mean age 50.7±17.6 years) with acute and subacute back pain were followed up. Out of them 127 (91%) patients were found to have nonspecific (musculoskeletal) pain; 13 (9%) had discogenic radiculopathy. All the patients were informed of the benign nature of the disease, the high probability of its rapid resolution, the feasibility of abandoning prolonged bedrest, and the lack of need for physical therapy, reflexotherapy, massage, and manual therapy. To reduce pain, the patients received meloxicam 15 mg/day orally or intramuscularly or first 15 mg/day intramuscularly and then orally. The investigators assessed pain intensity with the numerical rating scale and functional activity restrictions with the Roland-Morris disability (RMD) questionnaire. Results. After treatment, the visual analogue scale pain intensity scores decreased from an average of 6.4 to 1.0; the RMD scores dropped from 6.8 to 1.4 (p<0.001). The duration of treatment averaged 11.0±4.4 days. Comparison of different meloxicam dosage regimens showed no significant differences; a positive result was noted in all cases. No adverse events were observed during treatment. Conclusion. The investigation has shown the high efficiency of management in patients with acute and subacute dorsalgia, by providing information to patients (an education conversation), by using meloxicam, and by applying a personalized approach (treatment for concomitant diseases and conditions). Refusing physiotherapy, massage, acupuncture, and manual therapy substantially reduces the cost of treatment in patients with acute dorsalgia.

acute dorsalgia, subacute dorsalgia, discogenic radiculopathy, back pain school, nonsteroidal anti-inflammatory drugs, meloxicam

1. Яхно НН, Кукушкин МЛ, Чурюканов МВ, Сыровегин АВ. Результаты открытого мультицентрового исследования «МЕРИДИАН» по оценке распространенности болевых синдромов в амбулаторной практике и терапевтических предпочтений врачей. Российский журнал боли. 2012;(3):10-4. [Yakhno NN, Kukushkin ML, Churyukanov MV, Syrovegin AV. The results of the open multicenter study MERIDIAN to assess the prevalence of pain syndromes in outpatient practice and therapeutic preferences of doctors. Rossiiskii zhurnal boli. 2012;(3):10-4. (In Russ.)].

2. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Aug 22;386(9995): 743-800. doi: 10.1016/S0140-6736(15)60692-4. Epub 2015 Jun 7.

3. Koes BW, van Tulder M, Lin CW, et al. An updated overview of clinical guidelines for the management of non-specific low back pain in primary care. Eur Spine J. 2010 Dec;19(12): 2075-94. doi: 10.1007/s00586-010-1502-y. Epub 2010 Jul 3.

4. Hoy D, Brooks P, Blyth F, Buchbinder R. The Epidemiology of low back pain. Best Pract Res Clin Rheumatol. 2010 Dec;24(6):769-81. doi: 10.1016/j.berh.2010.10.002.

5. Wong J, Cote P, Sutton DA, et al. Clinical practice guidelines for the noninvasive management of low back pain: A systematic review by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration. Eur J Pain. 2017 Feb;21(2):201-216. doi: 10.1002/ejp.931. Epub 2016 Oct 6.

6. Low Back Pain and Sciatica in Over 16s: Assessment and Management. Clinical Guidelines. London: National Institute for Health and Care Excellence (UK); 2016. www.nice.org.uk/guidance/ng5

7. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Eur Spine J. 2018 Jan;27(1):60-75. doi: 10.1007/s00586-017-5099-2. Epub 2017 Apr 20.

8. Qaseem A, Wilt TJ, McLean RM, Forciea MA. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Apr 4;166(7): 514-530. doi: 10.7326/M16-2367. Epub 2017 Feb 14.

9. Kuritzky L, Samraj GP. Nonsteroidal antiinflammatory drugs in the treatment of low back pain. J Pain Res. 2012;5:579-90. doi: 10.2147/JPR.S6775. Epub 2012 Nov 28.

10. Wong JJ, Cote P, Ameis A, et al. Are nonsteroidal anti-inflammatory drugs effective for the management of neck pain and associated disorders, whiplash-associated disorders, or non-specific low back pain? A systematic review of systematic reviews by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration. Eur Spine J. 2016 Jan;25(1): 34-61. doi: 10.1007/s00586-015-3891-4. Epub 2015 Apr 1.

11. Henschke N, Maher CG, Refshauge KM, et al. Prognosis in patients with recent onset low back pain in Australian primary care: inception cohort study. BMJ. 2008 Jul 7;337:a171. doi: 10.1136/bmj.a171.

12. Poquet N, Lin CW, Heymans MW, et al. Back schools for acute and subacute non-specific low-back pain. Cochrane Database Syst Rev. 2016 Apr 26;4:CD008325. doi: 10.1002/ 14651858.CD008325.pub2.

13. Cohen SP, Hooten WM. Advances in the diagnosis and management of neck pain. BMJ. 2017 Aug 14;358:j3221. doi: 10.1136/bmj.j3221

14. Hincapie CA, Cassidy JD, Cote P, et al. Chiropractic spinal manipulation and the risk for acute lumbar disc herniation: a belief elicitation study. Eur Spine J. 2018 Jul;27(7):1517-1525. doi: 10.1007/s00586-017-5295-0. Epub 2017 Sep 18.

15. Ojha HA, Wyrsta NJ, Davenport TE, et al. Timing of Physical Therapy Initiation for Nonsurgical Management of Musculoskeletal Disorders and Effects on Patient Outcomes: A Systematic Review. J Orthop Sports Phys Ther. 2016 Feb;46(2):56-70. doi: 10.2519/jospt.2016. 6138. Epub 2016 Jan 11.

16. Vanti C, Andreatta S, Borghi S, et al. The effectiveness of walking versus exercise on pain and function in chronic low back pain: a systematic review and meta-analysis of randomized trials. Disabil Rehabil. 2017 Dec 5:1-11. doi: 10.1080/09638288.2017.1410730. [Epub ahead of print].

17. Герасимова ОН, Парфенов ВА. Лечение острой неспецифической боли в спине в амбулаторной практике. Неврология, нейропсихиатрия, психосоматика. 2009;1(3-4): 40-6. [Gerasimova ON, Parfenov VA. Treatment for acute nonspecific back pain in outpatient practice. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2009;1(3-4):40-6. (In Russ.)]. doi: 10.14412/2074-2711-2009-54

18. Насонов ЕЛ, Яхно НН, Каратеев АЕ и др. Общие принципы лечения скелетно-мышечной боли: междисциплинарный консенсус. Научно-практическая ревматология. 2016;54(3):247-65. [Nasonov EL, Yakhno NN, Karateev AE, et al. General principles of treatment for musculoskeletal pain: interdisciplinary consensus. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2016;54(3):247-65. (In Russ.)]. doi: 10.14412/ 1995-4484-2016-247-265

19. Singh G, Lanes S, Triadafilopoulos S. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med. 2004 Jul 15;117(2):100-6.

20. Hawkey C, Kahan A, Steinbrü ck K, et al. Gastrointestinal tolerability of meloxicam compared diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol. 1998 Sep;37(9):937-45.